Effects of Etravirine Versus Placebo on Health-Related Quality of Life in Treatment-Experienced HIV Patients as Measured by the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) Questionnaire in the DUET Trials

REFERENCES

• World Health Organization. AIDS Epidemic Update 2009. www unaids org 2009. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2009/2009epidemic_update.asp.
   Google Scholar
• Chearskul P, Rongkavilit C, Al-Tatari H, Asmar B. New antiretroviral drugs in clinical use. Indian J Pediatr. 2006;73(4):335–341.
   PubMedGoogle Scholar
• Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation Pls, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect. 2008;57(1):1–10.
   PubMed Web of Science ®Google Scholar
• Fauci AS. The AIDS epidemic--considerations for the 21st century. N Engl J Med. 1999;341(14):1046–1050.
   PubMed Web of Science ®Google Scholar
• van Sighem Al, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiret-roviral therapy. AIDS. 2003;17(15):2227–2236.
   PubMed Web of Science ®Google Scholar
• Palella FJJr, Delaney KM, Moorman AC,. Declining mor-bidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362(9377):22–29.
   PubMed Web of Science ®Google Scholar
• Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhib-itor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(12):4680–4686.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Larder BA. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimi-crob Agents Chemother 2002;46(3):909–912.
   PubMed Web of Science ®Google Scholar
• Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmis-sion fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 2003;187(4):683–686.
   PubMed Web of Science ®Google Scholar
• Grossman HA, Sullivan PS, Wu AW. Quality of life and HIV: current assessment tools and future directions for clinical practice. AIDS Read. 2003;13(12):583–587.
   PubMedGoogle Scholar
• Gulick RM. Current antiretroviral therapy: an overview. Qua/ Life Res. 1997;6(6):471–474.
   PubMed Web of Science ®Google Scholar
• Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170(2):229–238.
   PubMed Web of Science ®Google Scholar
• Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S98–102.
   PubMed Web of Science ®Google Scholar
• Cahn P, Haubrich R, Leider J, et al. Pooled 24-week results of DUET-1 and -2: TMC125 (etravirine;ETR) vs placebo in 1203 treatment-experienced HIV-1-infected patients. In: Program and abstracts from the 47th Inter-science Conference on Antimicrobial Agents and Che-motherapy; September 2007; Chicago, IL. Abstract: H–717.
   Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a ran-domised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):39–48.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29–38.
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(i7):2289–2300.
   PubMed Web of Science ®Google Scholar
• Tibotec Therapeutics (via PR Newswire). FDA Approves INTELENCE (etravirine) for HIV Combination Therapy. Press release. 2008.
   Google Scholar
• Tibotec Pharmaceuticals. Intelence (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy. Press release. 2008.
   Google Scholar
• EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16(3)1 99–208.
   Google Scholar
• Cella D, McCain NL, Peterman AH, Mo F, Wolen D. Devel-opment and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHL) quality of life instrument. Qual Life Res. 1996;5(4):450–463.
   PubMed Web of Science ®Google Scholar
• Peterman AH, Cella D, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHL) quality of life instrument. Qual Life Res. 1997;6(6):572–584.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sci-ences. New York: Academic Press; 1977.
   Google Scholar
• Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important differ-ence. Control Clin Trials. 1989;10(4):407–415.
   PubMedGoogle Scholar
• Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consen-sus. J Clin Epidemiol. 2005;58(12):1217–1219.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase ll study. Health Qual Life Outcomes. 2006;4:71.
   PubMed Web of Science ®Google Scholar
• Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523–1532.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health sta-tus measures. Mayo Clin Proc. 2002;77(4):371–383.
   PubMed Web of Science ®Google Scholar
• Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics. 2006;24(8):751–765.
   PubMed Web of Science ®Google Scholar
• Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS. 2000;11(10):659–665.
   PubMed Web of Science ®Google Scholar
• Earthman CP, Reid PM, Harper IT, Ravussin E, Howell WH. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. J Parenter Enteral Nutr 2002 ;26(6):357–365.
   PubMed Web of Science ®Google Scholar
• Sikkema KJ, Hansen NB, Meade CS, Kochman A, Lee RS. Improvements in health-related quality of life following a group intervention for coping with AIDS-bereavement among HIV-infected men and women. Qual Life Res. 2005;14(4):991–1005.
   PubMed Web of Science ®Google Scholar
• Dubois D, Smets E, Vangeneugden T, et al. Improved qual-ity of life in treatment-experienced HIV patients treated with TMC114/r versus control protease inhibitors: results of POWER 1 and 2 Functional Assessment of HIV Infection (FAH). In: Program and abstracts from the 16th Interna-tional AIDS Conference; 2006; Toronto, Canada.
   Google Scholar
• Casado A, Badia X, Consiglio E, et al. Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy). HIV Clin Trials. 2004 ;5(3):132–139.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr 2004;37(1)1140–1146.
   Web of Science ®Google Scholar
• Nieuwkerk PT, Gisolf EH, Colebunders R, Wu AW, Danner SA, Sprangers MA. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/ saquinavir therapy. AIDS. 2000;14(2)1 81–187.
   Web of Science ®Google Scholar
• van Leth F, Conway B, Laplume H, et al. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antivir Ther. 2004;9(5):721–728.
   PubMed Web of Science ®Google Scholar
• Badia X, Podzamczer D, Garcia M, Lopez-Lavid CC, Consiglio E. A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQ0L-HIV Validation Group. Medical Outcomes Study HIV Health Survey. AIDS. 1999;13(13):1727–1735.
   PubMed Web of Science ®Google Scholar
• Eriksson LE, Bratt GA, Sandstrom E, Nordstrom G. The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life. Health Qual Life Outcomes. 2005;3:32.
   PubMedGoogle Scholar
• Call SA, Klapow JC, Stewart KE, Westfall AO, Mellinger AP, DeMasi RA, Centor R, Saag MS. Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res. 2000;9(9):977–985.
   PubMed Web of Science ®Google Scholar
• Murri R, Fantoni M, Del Borgo C, et al. Determinants of health-related quality of life in HIV-infected patients. AIDS Care. 2003;15(4):581–590.
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Med Care. 2000;38(4):404–410.
   PubMed Web of Science ®Google Scholar